Cognivue taps Fred Ma as chief medical officer, senior vice president
Cognivue has named Dr. Fred Ma to the role of chief medical officer and senior vice president, effective immediately. His nearly four-decade career spans global medical device and pharmaceutical development and commercialization, as well as advancing neurological disorder treatments, therapies and prevention as a neurosurgeon.
“Dr. Ma’s leadership has earned the highest respect among his clinical, industry and research peers worldwide. He has the rare ability to translate extensive medical and scientific knowledge into accessible insights and market-leading products,” said Tom O’Neill, president and CEO of Cognivue. “We believe he will help take us to the next level with even better products and deeper relationships to come. His contributions in supporting existing customers and extending clinical validation through studies, manuscripts and more will be invaluable.”
Ma was most recently president and COO of Innovative Health Sciences, the immunology drug and subcutaneous drug infusion device company. He has served as chief medical officer for Koru Medical Systems, Innovacyn and GE Healthcare, and held leadership roles at Johnson & Johnson and Merck, among others. Ma managed more than 100 new product developments with more than 600 successful clinical trials and regulatory filings in the Americas, Europe, Africa and Asia-Pacific.
Before accepting his first industry position in 1990, Ma was a practicing neurosurgeon at the China-Japan Friendship Hospital in Beijing and the University of Tokyo Hospital, including tenures as attending physician and resident general chief. He is Board certified in Japan and China in neurosurgery, functional neurosurgery and oncology.
“The passion shown by Dr. Ma for cognitive assessment and evaluation was evident from our first conversation," O'Neill said. "Among his many accomplishments, he has been involved in drug research and clinical investigation for cognitive modulation on ADHD, Alzheimer’s, and dementia, plus near-infrared light therapy device development for TBI and PTSD. It’s hard to overstate his potential contributions as he becomes part of our fast-growing organization."